On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity, are no longer in shortage, The agency’s decision will ...
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...